Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94)

Radiotherapy and Oncology

Volumn 104, Issue 2, 2012, Pages 213-218

  Ghadjar, Pirus ^a   Simcock, Mathew ^b   Zimmermann, Frank ^c   Betz, Michael ^d   Bodis, Stephan ^e   Bernier, Jacques ^f   Studer, Gabriela ^g   Aebersold, Daniel M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e CANTONAL HOSPITAL AARAU   (Switzerland)

^f CLINIQUE DE GENOLIER   (Switzerland)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Chemotherapy; Cisplatin; Head and neck cancer; Hyperfractionated radiotherapy; Late radiation toxicity

Indexed keywords

CISPLATIN;

ACUTE DISEASE; ADULT; ADVANCED CANCER; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DYSPHAGIA; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; HYPERFRACTIONATED RADIOTHERAPY; LATE RADIATION TOXICITY; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; WEIGHT REDUCTION;

ADULT; AGED; ANALYSIS OF VARIANCE; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; CONFIDENCE INTERVALS; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865782352     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2012.05.004     Document Type: Article

References (21)

1. J. Bourhis, J. Overgaard, and H. Audry Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis Lancet 368 2006 843 854
2. W. Budach, T. Hehr, and V. Budach A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck BMC Cancer 6 2006 28
3. J.P. Pignon, A. le Maître, and E. Maillard Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients Radiother Oncol 92 2009 4 14
4. K.K. Fu, T.F. Pajak, and A. Trotti A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003 Int J Radiat Oncol Biol Phys 48 2000 7 16
5. D. Rades, F. Fehlauer, and M. Sheikh-Sarraf Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer Head Neck 30 2008 235 241
6. C.L. Zuur, Y.J. Simis, and P.E. Lansdaal Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis Int J Radiat Oncol Biol Phys 68 2007 1320 1325
7. J.M. Henk Controlled trials of synchronous chemotherapy with radiotherapy in head and neck cancer: overview of radiation morbidity Clin Oncol 9 1997 308 312
8. S. Staar, V. Rudat, and H. Stuetzer Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-Results of a multicentric randomized German trial in advanced head-and-neck cancer Int J Radiat Oncol Biol Phys 50 2001 1161 1171
9. D.M. Brizel, M.E. Albers, and S.R. Fisher Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer N Engl J Med 338 1998 1798 1804
10. B. Jeremic, Y. Shibamoto, and B. Milicic Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial J Clin Oncol 18 2000 1458 1464
11. V. Budach, M. Stuschke, and W. Budach Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 prospective randomized trial J Clin Oncol 23 2005 1125 1135
12. R.J. Bensadoun, K. Bénézery, and O. Dassonville French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2-years (FNCLCC-GORTEC) Int J Radiat Oncol Biol Phys 64 2006 983 994
13. P. Ghadjar, M. Simcock, and G. Studer Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94) Int J Radiat Oncol Biol Phys 82 2012 524 531
14. D.M. Brizel, and R. Esclamado Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, and conundrum J Clin Oncol 24 2006 2612 2617
15. K.K. Ang Multidisciplinary management of locally advanced SCCHN: optimizing treatment outcomes The Oncologist 13 2008 899 910
16. M. Machtay, J. Moughan, and A. Trotti Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis J Clin Oncol 26 2008 3582 3589
17. F. Meyer, A. Fortin, C. Shu Wang, G. Liu, and I. Bairati Predictors of severe acute and late toxicities in patients with localized head and neck cancer treated with radiation therapy Int J Radiat Oncol Biol Phys 82 2012 1454 1462
18. A. Eisbruch, L.H. Marsh, and M.K. Martel Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: assessment of target coverage and noninvolved tissue sparring Int J Radiat Oncol Biol Phys 41 1998 559 568
19. W.M. Mendenhall, R.J. Amdur, and J.R. Palta Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls J Clin Oncol 24 2006 2618 2623
20. C.M. Nutting, J.P. Morden, and K.J. Harrington Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial Lancet Oncol 12 2011 127 136
21. F.Y. Feng, H.M. Kim, and T.H. Lyden Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results J Clin Oncol 28 2010 2732 2738